Opus Investment Management’s AbbVie ABBV Stock Holding History

Opus Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.07M	Hold	41,700	–	–	5.41%	3
2025 Q4	$9.53M	Hold	41,700	–	–	5.8%	3
2025 Q3	$9.66M	Hold	41,700	–	–	5.99%	3
2025 Q2	$7.74M	Hold	41,700	–	–	5.14%	3
2025 Q1	$8.74M	Hold	41,700	–	–	6.23%	2
2024 Q4	$7.41M	Hold	41,700	–	–	5.47%	4
2024 Q3	$8.23M	Hold	41,700	–	–	5.78%	2
2024 Q2	$7.15M	Hold	41,700	–	–	4.62%	2
2024 Q1	$7.59M	Hold	41,700	–	–	4.96%	2
2023 Q4	$6.46M	Hold	41,700	–	–	3.71%	3
2023 Q3	$6.22M	Hold	41,700	–	–	3.83%	3
2023 Q2	$5.62M	Hold	41,700	–	–	2.02%	10
2023 Q1	$6.65M	Hold	41,700	–	–	2.4%	5
2022 Q4	$6.74M	Sell	41,700 -20,000	-32%	-$3.07M	2.4%	4
2022 Q3	$8.28M	Hold	61,700	–	–	1.93%	3
2022 Q2	$9.45M	Hold	61,700	–	–	2.05%	2
2022 Q1	$10M	Hold	61,700	–	–	1.54%	7
2021 Q4	$8.35M	Hold	61,700	–	–	1.19%	11
2021 Q3	$6.66M	Hold	61,700	–	–	1.02%	16
2021 Q2	$6.95M	Hold	61,700	–	–	1.05%	16
2021 Q1	$6.68M	Sell	61,700 -5,200	-8%	-$556K	0.98%	17
2020 Q4	$7.17M	Hold	66,900	–	–	1.12%	14
2020 Q3	$5.86M	Hold	66,900	–	–	1.11%	23
2020 Q2	$6.57M	Hold	66,900	–	–	1.33%	11
2020 Q1	$5.1M	Hold	66,900	–	–	1.07%	21
2019 Q4	$5.92M	Hold	66,900	–	–	0.97%	20
2019 Q3	$5.07M	Hold	66,900	–	–	0.88%	32
2019 Q2	$4.87M	Hold	66,900	–	–	0.92%	30
2019 Q1	$5.39M	Hold	66,900	–	–	1.07%	21
2018 Q4	$6.17M	Hold	66,900	–	–	1.33%	5
2018 Q3	$6.33M	Hold	66,900	–	–	1.1%	11
2018 Q2	$6.2M	Buy	66,900 +200	+0.3%	+$19.5K	1.12%	8
2018 Q1	$6.31M	Sell	66,700 -10,000	-13%	-$1.1M	1.16%	11
2017 Q4	$7.42M	Sell	76,700 -5,000	-6%	-$471K	1.32%	6
2017 Q3	$7.26M	Sell	81,700 -15,000	-16%	-$1.14M	1.32%	6
2017 Q2	$7.01M	Sell	96,700 -5,000	-5%	-$336K	1.19%	6
2017 Q1	$6.63M	Hold	101,700	–	–	1.13%	9
2016 Q4	$6.37M	Hold	101,700	–	–	1.12%	11
2016 Q3	$6.41M	Hold	101,700	–	–	1.09%	12
2016 Q2	$6.3M	Buy	101,700 +5,000	+5%	+$305K	1.11%	13
2016 Q1	$5.52M	Buy	96,700 +20,000	+26%	+$1.11M	1.06%	13
2015 Q4	$4.54M	Hold	76,700	–	–	0.81%	38
2015 Q3	$4.17M	Hold	76,700	–	–	0.79%	37
2015 Q2	$5.15M	Hold	76,700	–	–	0.94%	20
2015 Q1	$4.49M	Hold	76,700	–	–	0.79%	19
2014 Q4	$5.02M	Hold	76,700	–	–	0.9%	12
2014 Q3	$4.43M	Hold	76,700	–	–	0.84%	20
2014 Q2	$4.33M	Buy	76,700 +12,000	+19%	+$630K	0.85%	33
2014 Q1	$3.33M	Buy	64,700 +55,000	+567%	+$2.78M	0.77%	49
2013 Q4	$512K	Hold	9,700	–	–	0.14%	71
2013 Q3	$434K	Buy	+9,700	New	+$430K	0.1%	72

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Opus Investment Management's ABBV Position: Q1 2026 in Review

Opus Investment Management held its AbbVie (ABBV) position steady in Q1 2026 at 41,700 shares worth $9.07M. The position accounts for 5.41% of the portfolio, ranked #3.

Opus Investment Management first reported a position in ABBV in Q3 2013 and has held it in 51 quarters since. The position peaked at $10M in Q1 2022. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Opus Investment Management held 41,700 shares of AbbVie worth $9.07M as of Q1 2026.
Opus Investment Management left its AbbVie share count unchanged in Q1 2026.
AbbVie made up 5.41% of Opus Investment Management's portfolio in Q1 2026, its #3 holding.
Opus Investment Management first reported a position in AbbVie in Q3 2013 and has held it in 51 quarters since.
Opus Investment Management's AbbVie position peaked at $10M in Q1 2022.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Opus Investment Management's 13F filing for Q1 2026, filed 13 May 2026.